Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2022 13:00 ET | Source: DelveInsight Business Research LLP

Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight

New York, USA, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight ...
December 07, 2017 16:05 ET | Source: Cascadian Therapeutics, Inc.

Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer

SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
September 11, 2017 06:00 ET | Source: Cascadian Therapeutics, Inc.

Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress

Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...
August 28, 2017 08:30 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress

SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will...
June 08, 2017 08:00 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases

SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
December 07, 2016 07:00 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration

Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...